Vol. 44 (5): 874-881, September – October, 2018

doi: 10.1590/S1677-5538.IBJU.2017.0471


Juan Manuel Ochoa-Lopez 1, Bernardo Gabilondo-Pliego 1, Sylvain Collura-Merlier 1, Jaime O. Herrera-Caceres 1, Mariano Sotomayor de Zavaleta 1, Francisco Tomas Rodriguez-Covarrubias 1, Guillermo Feria-Bernal 1, Fernando Gabilondo-Navarro 1, Ricardo Alonso Castillejos-Molina 1
1 Department of Urology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México


Purpose: To provide data of the incidence and management of common urological malignancies in renal transplant recipients.

Materials and Methods: We conducted a retrospective analysis of a prospective database from August 1967 to August 2015. A descriptive analysis of the sample was performed.

Results: Among 1256 consecutive RTR a total of 88 patients developed malignancies (7%). There were 18 genitourinary tumors in the 16 patients (20.45 % of all malignant neoplasms), incidence of 1.27%. The most common neoplasm encounter was renal cancer (38.8%), followed by urothelial carcinoma (33.3%). Median follow-up of transplantation was 197 months (R, 36-336). Mean time from RT to cancer diagnosis 89±70 months (R, 12-276). CsA and AZA was the most common immunosuppression regimen in 68.75%. Mean follow-up after diagnosis was 103±72 months (R 10-215). Recurrence free survival rate of 100%. Overall survival of 89.5% of the sample; there were two non-related cancer deaths during follow-up. Conclusions: The incidence of neoplasms in RTR was lower than in other series, with favorable functional and oncologic results after treatment. This suggests that actions to reduce the risk of these malignancies as well as a strict follow-up are mandatory for an early detection and treatment.


Keywords: Neoplasms; Urinary Tract; Kidney Transplantation

[Full Text]